A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Title: A Study to See if BEBT-209 Combined With Chemotherapy Works to Treat People With Triple-Negative Breast Cancer Researchers want to learn if a new drug called BEBT-209 works to treat people with a specific type of breast cancer. This cancer is called locally advanced or metastatic triple-negative breast cancer (TNBC). The study has two parts. In the first part, researchers want to see if the new drug combination can shrink tumors. In the second part, researchers want to see if this treatment helps people live longer. Researchers will put participants into two groups by chance. This is like flipping a coin. Group 1: Participants get BEBT-209 plus two chemotherapy drugs. These drugs are Carboplatin and Gemcitabine. Group 2: Participants get only the two chemotherapy drugs. Researchers will group people based on the treatments they had in the past. Researchers will also check: How long the treatment keeps the cancer from growing. This is called progression-free survival (PFS). If the treatment is safe. Researchers will look for adverse events (AE), such as low blood cell counts. How participants feel. This is called health-related quality of life (HRQoL). How the body uses the drug.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18-75 lat
- •Potwierdzony rozpoznaniem rak piersi potrójnie ujemny (zaawansowany lub z przerzutami)
- •Co najmniej jeden widoczny na badaniach guz
- •Dostanie przynajmniej jedną, ale nie więcej niż dwie wcześniejsze leczenia
- •Ogólny stan zdrowia pozwala na uczestnictwo w badaniu
- •Oczekiwana długość życia co najmniej 12 tygodni
- •Prawidłowe wyniki badań krwi i funkcji narządów
- •Wyzdrowiał z poprzednich skutków ubocznych leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 18, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (2)
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Hunan Cancer Hospital
Changsha, China
Trial contact
Kegang Jiang, Master
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.